PROCEPT BioRobotics (NasdaqGM:PRCT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsKevin Waters - EVP and CFOLarry L. Wood - President and CEOMatt Bacso - VP of Investor RelationsStephanie Piazzola - VP of Equity Research and Medical TechnologyConference Call ParticipantsBrandon Vazquez - Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDanielle Antalffy - Senior AnalystJosh Jennings - Managing Director and Senior AnalystMatthew O'Brien - Ma ...

PROCEPT BioRobotics (NasdaqGM:PRCT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsKevin Waters - CFOLarry Wood - CEOMatt Bacso - VP of Investor RelationsStephanie Piazzola - VP of Equity Research and Medical TechnologyConference Call ParticipantsBrandon Vazquez - Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDanielle Antalffy - Senior AnalystJosh Jennings - Managing Director and Senior AnalystMatthew O'Brien - Managing Director and Senio ...

PROCEPT BioRobotics (NasdaqGM:PRCT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker12Good afternoon, welcome to the PROCEPT BioRobotics fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the conference over to Matt Bacso, Vice President, Investor Relations, for a few intr ...

Summary of PROCEPT BioRobotics FY Conference Call (December 02, 2025) Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically in urology and robotic-assisted procedures Key Points and Arguments Utilization and Inventory Management - The CEO clarified that the decline in HP sales does not indicate a problem with procedure volumes but rather an inventory workdown issue [3][4] - The company is focusing on procedure volume rather than just stocking orders, which are seen as noise in the system [3][4] - Adjustments were made to guidance based on the analysis that many sites were carrying excess inventory [4] Procedure Growth - The company is pleased with the adoption of its therapy and is focusing on procedural growth [5] - The CEO emphasized the importance of efficient launches and training for new centers to drive better utilization [12][13] - A pilot program was initiated to improve the launch process, which has shown benefits [12] Patient Engagement and Market Penetration - The CEO discussed the need to educate patients about the benefits of their procedures, particularly in terms of safety and outcomes [37][38] - There is a significant opportunity to convert patients who are currently hesitant to undergo procedures due to fears of complications [25][28] Competitive Landscape - The company believes it occupies a unique position in the market, offering effective procedures with a low complication profile compared to other options [42] - The CEO highlighted the need to change the narrative around non-receptive procedures, which may initially seem attractive but lack durability [46] Capital Sales and Replacement Cycle - The capital sales team performed well despite increased scrutiny in the capital process, with a strong outlook for future placements [52][54] - The company is developing a cohesive replacement strategy for its AquaBeam systems, which is expected to become significant in 2026 [58][61] Financial Guidance - The CEO expressed confidence in the guidance provided, which reflects a status quo but also acknowledges opportunities for improvement [66][68] - Better commercial execution and the ability to replace legacy systems are seen as key drivers for achieving the high end of guidance [68] Reimbursement Landscape - Facility payments to hospitals have increased by 5% year-over-year, making the economic case for the company's procedures favorable [70] - The CEO noted that the adoption of aquablation therapy is driven more by clinical outcomes than by economic factors [71] Marketing and Education - The company plans to utilize social media and referral community education rather than large-scale advertising to promote its procedures [77] Additional Important Insights - The management team is focused on improving the training and specialization of their field staff to enhance overall performance [22][23] - The CEO's experience from previous roles is being leveraged to improve operational efficiency and patient outcomes at PROCEPT [24][25] This summary captures the essential points discussed during the conference call, highlighting the company's strategic focus on procedure growth, patient education, and operational efficiency in the medical technology sector.